Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Osteosarcoma 1Neuroblastoma 1

Interventions

plerixafor 1pazopanib 1lorukafusp alfa 1liposomal doxorubicin 1imetelstat 1Temozolomide 1Pentetic Acid 1Palliative Care 1Nutritional Support 1Minocycline 1MAGEA3 protein, human 1MAGEA1 protein, human 1Heparin 1Glutamine 1Gemcitabine 1GRN163L peptide 1Filgrastim 1Erlotinib Hydrochloride 1Electroacupuncture 1Docetaxel 1Dexamethasone 1Celecoxib 1Calcium Carbonate 1Analgesia 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Osteosarcoma × lorukafusp alfa × Clear all
NCT03209869 2022-09-13

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

University of Wisconsin, Madison

Phase 1 Withdrawn
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡